Xbrane Biopharma AB (XBRANE) — Working Capital to Net Assets Ratio
Xbrane Biopharma AB (XBRANE) has a Working Capital to Net Assets ratio of 57.5% as of December 2025. Working capital of Skr322.47 Million (current assets of Skr375.13 Million minus current liabilities of Skr52.66 Million) is measured against net assets of Skr560.65 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See XBRANE equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Xbrane Biopharma AB Working Capital to Net Assets (2012–2025)
This chart shows how Xbrane Biopharma AB's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 57.5%, reflecting working capital of Skr322.47 Million against net assets of Skr560.65 Million SEK. Check how tangible is Xbrane Biopharma AB's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Xbrane Biopharma AB (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Xbrane Biopharma AB (XBRANE) market capitalisation.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 57.5% | Skr322.47 Million | Skr560.65 Million | Skr375.13 Million | Skr52.66 Million | ▲ +24.9 pp |
| 2024 | 32.6% | Skr67.96 Million | Skr208.54 Million | Skr605.90 Million | Skr537.94 Million | ▼ -46.3 pp |
| 2023 | 78.9% | Skr135.14 Million | Skr171.34 Million | Skr461.69 Million | Skr326.56 Million | ▲ +13.7 pp |
| 2022 | 65.2% | Skr276.95 Million | Skr424.89 Million | Skr513.52 Million | Skr236.57 Million | ▼ -13.9 pp |
| 2021 | 79.1% | Skr341.34 Million | Skr431.74 Million | Skr561.01 Million | Skr219.67 Million | ▲ +7.1 pp |
| 2020 | 72.0% | Skr185.49 Million | Skr257.71 Million | Skr374.48 Million | Skr188.99 Million | ▲ +13.2 pp |
| 2019 | 58.8% | Skr108.32 Million | Skr184.32 Million | Skr247.94 Million | Skr139.62 Million | ▲ +58.4 pp |
| 2018 | 0.3% | Skr277.00K | Skr83.07 Million | Skr161.66 Million | Skr161.38 Million | ▼ -11.2 pp |
| 2017 | 11.5% | Skr10.21 Million | Skr88.41 Million | Skr28.10 Million | Skr17.89 Million | ▼ -23.5 pp |
| 2016 | 35.1% | Skr37.64 Million | Skr107.30 Million | Skr43.53 Million | Skr5.88 Million | ▲ +68.7 pp |
| 2015 | -33.6% | Skr-15.97 Million | Skr47.51 Million | Skr7.43 Million | Skr23.40 Million | ▼ -131.5 pp |
| 2014 | 97.9% | Skr6.17 Million | Skr6.30 Million | Skr6.56 Million | Skr390.70K | ▼ -2.1 pp |
| 2013 | 100.0% | Skr8.69 Million | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +0.0 pp |
| 2012 | 100.0% | Skr88.11K | Skr88.11K | Skr657.01K | Skr568.90K | — |